Table 2.
Antimicrobial resistance of dominant (unselected) population versus subpopulation from hypermutable P. aeruginosa isolates from CF patients
| Antibiotica | No. (%) of resistant isolates in population |
|||
|---|---|---|---|---|
| CFRCPA (n = 151) |
CFRCRJ (n = 43) |
|||
| Dominant population | Subpopulation | Dominant population | Subpopulation | |
| CAZ | 13 (8.6) | 45 (29.8)b | 2 (4.6) | 28 (65.1)b |
| CIP | 23 (15.2) | 44 (29.1)b | 0 | 1 (2.3) |
| IMP | 8 (5.3) | 89 (58.9)b | 0 | 13 (30.2)b |
| MEM | 4 (2.6) | 34 (22.5)b | 0 | 7 (16.2)b |
| TOB | 35 (23.2) | 52 (34.4)b | 0 | 2 (4.6) |
a
CAZ, ceftazidime; CIP, ciprofloxacin; IMP, imipenem; MEM, meropenem; TOB, tobramycin; CFRCPA, Cystic Fibrosis Reference Center in Porto Alegre; CFRCRJ, Cystic Fibrosis Reference Center in Rio de Janeiro.
b
Fisher's exact test, P ≤ 0.05.